Parametric Portfolio Associates buys $772,134,349 stake in Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) : Parametric Portfolio Associates scooped up 305,554 additional shares in Johnson & Johnson during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 6,266,307 shares of Johnson & Johnson which is valued at $772,134,349.Johnson & Johnson makes up approximately 1.17% of Parametric Portfolio Associates’s portfolio.

Other Hedge Funds, Including , Valley National Advisers Inc reduced its stake in JNJ by selling 509 shares or 1.16% in the most recent quarter. The Hedge Fund company now holds 43,492 shares of JNJ which is valued at $5,359,084. Johnson & Johnson makes up approx 2.70% of Valley National Advisers Inc’s portfolio.Wetherby Asset Management Inc boosted its stake in JNJ in the latest quarter, The investment management firm added 1,359 additional shares and now holds a total of 53,754 shares of Johnson & Johnson which is valued at $6,623,568. Johnson & Johnson makes up approx 1.41% of Wetherby Asset Management Inc’s portfolio.Convergence Investment Partners reduced its stake in JNJ by selling 11,036 shares or 43.46% in the most recent quarter. The Hedge Fund company now holds 14,359 shares of JNJ which is valued at $1,769,316. Johnson & Johnson makes up approx 0.23% of Convergence Investment Partners’s portfolio.Sitrin Capital Management boosted its stake in JNJ in the latest quarter, The investment management firm added 1,833 additional shares and now holds a total of 48,127 shares of Johnson & Johnson which is valued at $5,979,298. Johnson & Johnson makes up approx 4.58% of Sitrin Capital Management’s portfolio.

Johnson & Johnson opened for trading at $119.3 and hit $120.13 on the upside on Monday, eventually ending the session at $119.92, with a gain of 0.74% or 0.88 points. The heightened volatility saw the trading volume jump to 50,74,924 shares. Company has a market cap of $328,086 M.

On the company’s financial health, Johnson & Johnson reported $1.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 19, 2016. Analyst had a consensus of $1.68. The company had revenue of $18482.00 million for the quarter, compared to analysts expectations of $17985.80 million. The company’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.71 EPS.

Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by UBS on Jul 20, 2016 to “Buy”, Firm has raised the Price Target to $ 137 from a previous price target of $126 .Company shares were Reiterated by RBC Capital Mkts on Jul 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 133 from a previous price target of $125 .Standpoint Research Initiated Johnson & Johnson on May 20, 2016 to “Sell”, Price Target of the shares are set at $94.

Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company’s research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Johnson & Johnson - Is it time to Sell?

Top Brokerage Firms are advising their investors on Johnson & Johnson. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.